The DOI matches its Crossref record; 49 of the 52 references it cites were found in a registry or an index.
Farnesoid X receptor antagonizes nuclear factor κB in hepatic inflammatory response
Open accessAbstract
The farnesoid X receptor (FXR) is a nuclear receptor that plays key roles in hepatoprotection by maintaining the homeostasis of liver metabolism. FXR null mice display strong hepatic inflammation and develop spontaneous liver tumors. In this report, we demonstrate that FXR is a negative modulator of nuclear factor κB (NF-κB)–mediated hepatic inflammation. Activation of FXR by its agonist ligands inhibited the expression of inflammatory mediators in response to NF-κB activation in both HepG2 cells and primary hepatocytes cultured in vitro . In vivo , compared with wild-type controls, FXR−/− mice displayed elevated messenger RNA (mRNA) levels of inducible nitric oxide synthase (iNOS), cyclooxygenase-2 (COX-2), interferon-inducible protein 10, and interferon-γ in response to lipopolysaccharide (LPS). Examination of FXR−/− livers showed massive necroses and inflammation after treatment with LPS at a dose that does not induce significant liver damage or inflammation in wild-type mice. Moreover, transfection of a constitutively active FXR expression construct repressed the iNOS, COX-2, interferon-inducible protein 10 and interferon-γ mRNA levels induced by LPS administration. FXR activation had no negative effects on NF-κB-activated antiapoptotic genes, suggesting that FXR selectively inhibits the NF-κB-mediated hepatic inflammatory response but maintains or even enhances the cell survival response. On the other hand, NF-κB activation suppressed FXR-mediated gene expression both in vitro and in vivo , indicating a negative crosstalk between the FXR and NF-κB signaling pathways. Our findings reveal that FXR is a negative mediator of hepatic inflammation, which may contribute to the critical roles of FXR in hepatoprotection and suppression of hepatocarcinogenesis. (Hepatology 2008;48:1632–1643.)
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“FXR agonists are known to alleviate endoplasmic reticulum stress and suppress oxidative damage by upregulating antioxidant and anti-apoptotic pathways [42, 43].”
From High-throughput human microfluidic organoid-on-a-chip platform for modeling liver diseases and screening nanotherapeutics. (2026) · cites this paper as [43]
Experimental — accuracy not yet measuredIn the citing paper
“Ablation of Nr1h4 (hereafter referred to as Fxr) not only promotes cholestasis but also NAFLD, NASH and HCC in mice (Kim et al., 2007; Lu et al., 2000; Wang et al., 2008; Watanabe et al., 2004; Yang et al., 2007).”
From Circadian Homeostasis of Liver Metabolism Suppresses Hepatocarcinogenesis (2016) · cites this paper as Wang et al., 2008
In the citing paper
“Next to their extensive effect on cell metabolism, they are able to mediate anti-inflammatory effects through direct interaction with other transcription factors, such as NF-κB or activator protein-1 (AP-1) [26,27], and even repress proinflammatory gene expression by interfering with TLR signaling.[28]”
From Nuclear receptors in liver fibrosis (2021) · cites this paper as [27]
In the citing paper
“In brief, FXR interacts with NF-κB signaling and inhibits pro-inflammatory genes (e.g., TNF-α, inducible nitric oxide synthase (iNOS), Cyclooxygeanse-2 (COX-2), CCL-2 and IL-1β)), while NF-κB activation reciprocally antagonizes FXR activity.[27,52,53]”
From Nuclear receptors in liver fibrosis (2021) · cites this paper as [27]
In the citing paper
“Additionally, FXR -/-mice were more susceptible to inflammatory stress, highlighting the anti- inflammatory properties of FXR.[27]”
From Nuclear receptors in liver fibrosis (2021) · cites this paper as [27]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The nuclear receptor superfamily: the second decade
Mangelsdorf, D. J., Thummel, C., Beato, M., Herrlich, P., Schütz, G., Umesono, K., Blumberg, B., Kastner, P., Mark, M., Chambon, P., et al. (1995) · Cell · doi:10.1016/0092-8674(95)90199-x · Cited by 6,964
NF-κB: linking inflammation and immunity to cancer development and progression
Karin, M., & Greten, F. R. (2005) · Nature reviews. Immunology · doi:10.1038/nri1703 · Cited by 3,175
Wang, C.-Y., Mayo, M., Korneluk, R., Goeddel, D., & Baldwin, A. (1998) · Science · doi:10.1126/science.281.5383.1680 · Cited by 2,950
IKKβ Links Inflammation and Tumorigenesis in a Mouse Model of Colitis-Associated Cancer
Greten, F. R., Eckmann, L., Greten, T. F., Park, J. M., Li, Z.-W., Egan, L. J., Kagnoff, M. F., & Karin, M. (2004) · Cell · doi:10.1016/j.cell.2004.07.013 · Cited by 2,433
NF-κB functions as a tumour promoter in inflammation-associated cancer
Pikarsky, E., Porat, R. M., Stein, I., Abramovitch, R., Amit, S., Kasem, S., Gutkovich-Pyest, E., Urieli-Shoval, S., Galun, E., & Ben‐Neriah, Y. (2004) · Nature · doi:10.1038/nature02924 · Cited by 2,423
Gender Disparity in Liver Cancer Due to Sex Differences in MyD88-Dependent IL-6 Production
Naugler, W. E., Sakurai, T., Kim, S., Maeda, S., Kim, K., Elsharkawy, A. M., & Karin, M. (2007) · Science · doi:10.1126/science.1140485 · Cited by 1,955
Targeted Disruption of the Nuclear Receptor FXR/BAR Impairs Bile Acid and Lipid Homeostasis
Sinal, C. J., Tohkin, M., Miyata, M., Ward, J. M., Lambert, G., & Gonzalez, F. J. (2000) · Cell · doi:10.1016/s0092-8674(00)00062-3 · Cited by 1,819
Endogenous Bile Acids Are Ligands for the Nuclear Receptor FXR/BAR
Wang, H., Chen, J., Hollister, K., Sowers, L. C., & Forman, B. M. (1999) · Molecular Cell · doi:10.1016/s1097-2765(00)80348-2 · Cited by 1,636
Self-citationAggarwal, B. B. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.09.003 · Cited by 1,586
A SUMOylation-dependent pathway mediates transrepression of inflammatory response genes by PPAR-γ
Pascual, G., Fong, A. L., Ogawa, S., Gamliel, A., Li, A. C., Perissi, V., Rose, D. W., Willson, T. M., Rosenfeld, M. G., & Glass, C. K. (2005) · Nature · doi:10.1038/nature03988 · Cited by 1,287
Flagged first, then by citations
3 of the 52 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Items 101–200 of 577
Tissue-specific function of farnesoid X receptor in liver and intestine
Zhu, Y., Li, F., & Guo, G. L. (2011) · Pharmacological Research · doi:10.1016/j.phrs.2010.12.018 · Cited by 103
Bile acids: From digestion to cancers
Baptissart, M., Vega, A., Maqdasy, S., Caira, F., Baron, S., Lobaccaro, J.-M. A., & Volle, D. H. (2013) · Biochimie · doi:10.1016/j.biochi.2012.06.022 · Cited by 97
“Moreover, in vitro experiments using humanHepG2 cells and primary hepatocyte culture show that FXRa agonist inhibits NF-kB transcriptional activity by decreasing its binding to DNA [78].”
BackgroundInfluentialGlycyrrhizin Alleviates Nonalcoholic Steatohepatitis via Modulating Bile Acids and Meta-Inflammation
Yan, T., Wang, H., Cao, L.-J., Wang, Q., Takahashi, S., Yagai, T., Li, G.-L., Krausz, K., Wang, G.-J., Gonzalez, F., et al. (2018) · Drug Metabolism And Disposition · doi:10.1124/dmd.118.082008 · Cited by 98
“FXR is known to have reciprocal regulation with NF-kB activation (Wang et al., 2008).”
BackgroundNuclear receptors as drug targets in cholestasis and drug-induced hepatotoxicity
Zollner, G., Wagner, M., & Trauner, M. (2010) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2010.03.005 · Cited by 91
“Moreover, FXR has potent anti-inflammatory properties since it inhibits hepatocellular NF-κB activation and induction of classical pro-inflammatory NF-κB target genes including tumor necrosis factor α, inducible nitric oxide synthase and cyclooxygenase-2 in hepatocytes (Wang et al., 2008).”
BackgroundFarnesoid X receptor: A “homeostat” for hepatic nutrient metabolism
Massafra, V., & van Mil, S. W. C. (2017) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2017.10.003 · Cited by 115
Physiological Role of Bile Acids Modified by the Gut Microbiome
Kiriyama, Y., & Nochi, H. (2021) · Microorganisms · doi:10.3390/microorganisms10010068 · Cited by 105
“FXR activation inhibits the expression of these genes by inhibiting the activity of nuclear factor-κB (NF-κB), and also has an anti-inflammatory function [142].”
BackgroundIracheta‐Vellve, A., Calenda, C. D., Petrášek, J., Ambade, A., Kodys, K., Adorini, L., & Szabó, G. (2018) · Hepatology Communications · doi:10.1002/hep4.1256 · Cited by 107
Role of FXR in Liver Inflammation During Nonalcoholic Steatohepatitis
Armstrong, L. E., & Guo, G. L. (2017) · Current Pharmacology Reports · doi:10.1007/s40495-017-0085-2 · Cited by 99
Impact of bile acids on the growth of human cholangiocarcinoma via FXR
Dai, J., Wang, H., Shi, Y. H., Dong, Y., Zhang, Y., & Wang, J. (2011) · Journal of Hematology & Oncology · doi:10.1186/1756-8722-4-41 · Cited by 85
D’Amore, C., Leva, F. S. D., Sepe, V., Renga, B., Gaudio, C. D., D’Auria, M. V., Zampella, A., Fiorucci, S., & Limongelli, V. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm401873d · Cited by 96
Bile Acid Receptors and Liver Cancer
Wang, X., Fu, X., Ness, C. V., Meng, Z., Ma, X., & Huang, W. (2012) · Current Pathobiology Reports · doi:10.1007/s40139-012-0003-6 · Cited by 92
Self-citationNonalcoholic fatty liver disease
Hardy, T., Anstee, Q. M., & Day, C. P. (2015) · Current Opinion in Gastroenterology · doi:10.1097/mog.0000000000000175 · Cited by 95
Toxic effects and molecular mechanism of doxorubicin on different organs – an update
Renu, K., Pureti, L. P., Vellingiri, B., & Gopalakrishnan, A. V. (2021) · Toxin Reviews · doi:10.1080/15569543.2021.1912099 · Cited by 88
Critical roles of bile acids in regulating intestinal mucosal immune responses
Sun, R., Xu, C., Feng, B., Gao, X., & Liu, Z. (2021) · Therapeutic Advances in Gastroenterology · doi:10.1177/17562848211018098 · Cited by 105
Huang, X., Zhao, W., & Huang, W. (2014) · Acta Pharmacologica Sinica · doi:10.1038/aps.2014.117 · Cited by 98
Self-citationNuclear receptors as therapeutic targets in liver disease: are we there yet?
Rudraiah, S., Zhang, X., & Wang, L. (2016) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010715-103209 · Cited by 87
“NRs can directly interact with proinflammatory transcription factors such as nuclear factor kappa B (NF-κB) and activator protein 1 (AP-1) (44).”
Hernandez, E. D., Zheng, L., Kim, Y., Fang, B., Liu, B., Valdez, R., Dietrich, W. F., Rucker, P. V., CHIANELLI, D., Schmeits, J., et al. (2019) · Hepatology Communications · doi:10.1002/hep4.1368 · Cited by 94
Ijssennagger, N., Janssen, A. W. F., Milona, A., Pittol, J. M. R., Hollman, D. A. A., Mokrý, M., Betzel, B., Berends, F. J., Janssen, I. M. C., van Mil, S. W. C., et al. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2016.01.016 · Cited by 94
Bile Acids, Their Receptors, and the Gut Microbiota
Poland, J. C., & Flynn, C. R. (2021) · Physiology · doi:10.1152/physiol.00028.2020 · Cited by 93
Nonsteroidal FXR Ligands: Current Status and Clinical Applications
Gege, C., Hambruch, E., Hambruch, N., Kinzel, O., & Kremoser, C. (2019) · Handbook of Experimental Pharmacology · doi:10.1007/164_2019_232 · Cited by 83
Thibaut, R., Gage, M., Pineda‐Torra, I., Chabrier, G., Venteclef, N., & Alzaïd, F. (2021) · FEBS Journal · doi:10.1111/febs.15877 · Cited by 97
Bai, X., Duan, Z., Deng, J., Zhang, Z., Fu, R., Zhu, C., & Fan, D. (2024) · Journal of Advanced Research · doi:10.1016/j.jare.2024.06.028 · Cited by 87
Obeticholic Acid: A New Era in the Treatment of Nonalcoholic Fatty Liver Disease
Abenavoli, L., Falalyeyeva, T. M., Boccuto, L., Tsyryuk, O., & Kobyliak, N. M. (2018) · Pharmaceuticals · doi:10.3390/ph11040104 · Cited by 93
“OCA also exerts significant anti-inflammatory and anti-fibrotic activities, selectively inhibiting the processes of liver inflammation mediated by the nuclear factor (NF)-κB while maintaining or enhancing the cell survival response [41].”
Immunology of bile acids regulated receptors
Fiorucci, S., Marchianò, S., Urbani, G., Giorgio, C. D., Distrutti, E., Zampella, A., & Biagioli, M. (2024) · Progress in Lipid Research · doi:10.1016/j.plipres.2024.101291 · Cited by 88
Wang, M.-Q., Zhang, K.-H., Liu, F.-L., Zhou, R., Zeng, Y., Chen, A., Yu, Y., Xia, Q., Zhu, C.-C., & Lin, C.-Z. (2023) · Phytomedicine · doi:10.1016/j.phymed.2023.155124 · Cited by 80
Self-citationBile acid-based therapies for non-alcoholic steatohepatitis and alcoholic liver disease
Li, T., & Chiang, J. Y. L. (2020) · HepatoBiliary Surgery and Nutrition · doi:10.21037/hbsn.2019.09.03 · Cited by 87
Role of nuclear factor κB in liver health and disease
Robinson, S. M., & Mann, D. A. (2010) · Clinical Science · doi:10.1042/cs20090549 · Cited by 81
Recent advances on FXR-targeting therapeutics
Panzitt, K., Zollner, G., Marschall, H., & Wagner, M. (2022) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2022.111678 · Cited by 88
“[93]) antagonizes FXR activity and target gene expression [88], resulting in reduced FXR expression levels and function in inflamed tissues [93].”
BackgroundLee, J., Seok, S., Yu, P.-F., Kim, K., Smith, Z., Rivas-Astroza, M., Zhong, S., & Kemper, J. (2012) · Hepatology · doi:10.1002/hep.25609 · Cited by 78
Jayakumar, S., & Loomba, R. S. (2019) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.15314 · Cited by 87
FXR modulators for enterohepatic and metabolic diseases
Wang, H., He, Q., Wang, G., Xu, X., & Hao, H. (2018) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2018.1527906 · Cited by 90
“A decade ago, FXR activation was proven to inhibit NF-κB pathway mediated inflammatory response [26].”
BackgroundGu, M., Zhao, P., Huang, J.-W., Zhao, Y., Wang, Y.-H., Li, Y., Li, Y.-F., Fan, S., Ma, Y.-M., Tong, Q., et al. (2016) · Frontiers in Pharmacology · doi:10.3389/fphar.2016.00345 · Cited by 76
“FXR agonists such as GW4064 and 6ECDCA were reported to inhibit NF-κB activity via FXR activation (Wang et al., 2008).”
BackgroundInfluentialSelf-citationSepe, V., Renga, B., Festa, C., D’Amore, C., Masullo, D., Cipriani, S., Leva, F. S. D., Monti, M. C., Novellino, E., Limongelli, V., et al. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm500889f · Cited by 89
Stojančević, M., Stankov, K., & Mikov, M. (2012) · Canadian Journal of Gastroenterology · doi:10.1155/2012/538452 · Cited by 77
“At the hepatic level, FXR is a negative modulator of NF-kB-mediated inflammation, reducing the expression of inflammatory mediators both in vivo and in vitro (69).”
BackgroundNuclear Receptors in the Control of the NLRP3 Inflammasome Pathway
Duez, H., & Pourcet, B. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.630536 · Cited by 85
Nikolaou, N., Gathercole, L., Marchand, L., Althari, S., Dempster, N. J., Green, C., van de Bunt, M., McNeil, C. A., Arvaniti, A., Hughes, B. A., et al. (2019) · Metabolism · doi:10.1016/j.metabol.2019.153947 · Cited by 86
Obeticholic acid protects against carbon tetrachloride-induced acute liver injury and inflammation
Zhang, D.-G., Zhang, C., Wang, J., Wang, B.-W., Wang, H., Zhang, Z., Chen, Y., Lu, Y., Li, T., Wang, J., et al. (2016) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2016.11.006 · Cited by 79
“FXRwas a negative modulator of NF-κB-mediated hepatic inflammation (Wang et al., 2008a,b; Kim et al., 2015; Bijsmans et al., 2015).”
BackgroundSystemic Inflammation and Acute-on-Chronic Liver Failure: Too Much, Not Enough
Laleman, W., Clària, J., der Merwe, V., Moreau, R., & Trebicka, J. (2018) · Canadian Journal of Gastroenterology and Hepatology · doi:10.1155/2018/1027152 · Cited by 84
Obesity and the liver: nonalcoholic fatty liver disease
Koppe, S. (2014) · Translational research · doi:10.1016/j.trsl.2014.06.008 · Cited by 74
The Immunomodulatory Role of Bile Acids
Sipka, S., & Bruckner, G. G. (2014) · International Archives of Allergy and Immunology · doi:10.1159/000366100 · Cited by 83
Roth, J. D., Feigh, M., Veidal, S. S., Fensholdt, L. K. D., Rigbolt, K. T. G., Hansen, H. H., Chen, L. C., Petitjean, M. M., Friley, W. W., Vrang, N., et al. (2018) · World Journal of Gastroenterology · doi:10.3748/wjg.v24.i2.195 · Cited by 79
Obeticholic acid for the treatment of primary biliary cirrhosis
Trivedi, P. J., Hirschfield, G. M., & Gershwin, M. E. (2015) · Expert Review of Clinical Pharmacology · doi:10.1586/17512433.2015.1092381 · Cited by 66
Cancer, Inflammation, and Insights from Ayurveda
Sumantran, V. N., & Tillu, G. S. (2012) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2012/306346 · Cited by 70
“As mentioned earlier, drugs modulating FXR activity [32, 33] and guggulsterone [13] have a potential role in treatment of colon cancer, which is associated with fatty diets and elevated secretion of bile.”
BackgroundCiaula, A. D., Bonfrate, L., Baj, J., Khalil, M., Garruti, G., Stellaard, F., Wang, H. H., Wang, D. Q. ‐., & Portincasa, P. (2022) · Nutrients · doi:10.3390/nu14234950 · Cited by 76
Nonacidic Farnesoid X Receptor Modulators.
Flesch, D., Cheung, S., Schmidt, J., Gabler, M., Heitel, P., Kramer, J., Kaiser, A., Hartmann, M., Lindner, M., Lüddens-Dämgen, K., et al. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00903 · Cited by 72
FXR ligands protect against hepatocellular inflammation via SOCS3 induction
Xu, Z., Huang, G., Gong, W., Zhou, P., Zhao, Y., Zhang, Y., Zeng, Y., Gao, M., Pan, Z., & He, F. (2012) · Cellular Signalling · doi:10.1016/j.cellsig.2012.04.015 · Cited by 71
Quercetin Inhibits LPS-Induced Inflammation and ox-LDL-Induced Lipid Deposition
Xue, F., Nie, X.-B., Shi, J.-P., Liu, Q., Wang, Z., Li, X., Zhou, J.-Q., Su, J., Xue, M.-M., Chen, W.-D., et al. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00040 · Cited by 71
“RNA Extraction and Quantitative Real Time PCR (qRT-PCR) See the supporting information (Wang et al., 2008).”
MethodSelf-citationNAFLD and HBV interplay - related mechanisms underlying liver disease progression
Tourkochristou, E., Assimakopoulos, S. F., Thomopoulos, K., Marangos, M., & Triantos, C. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.965548 · Cited by 70
Farnesoid X receptor activation protects the kidney from ischemia-reperfusion damage
Gai, Z.-B., Chu, L., Xu, Z., Song, X.-M., Sun, D., & Kullak-Ublick, G. (2017) · Scientific Reports · doi:10.1038/s41598-017-10168-6 · Cited by 70
PPAR agonists for the treatment of primary biliary cholangitis: Old and new tales
Colapietro, F., Gershwin, M. E., & Lleò, A. (2023) · Journal of Translational Autoimmunity · doi:10.1016/j.jtauto.2023.100188 · Cited by 81
“From 2016 the FDA has approved Obeticholic Acid (OCA) for use in PBC patients with inadequate response to or intolerance of UDCA; this is a farnesoid X receptor (FXR) agonist involved in regulation of bile acid transport with anti-fibrotic and anti-inflammatory effect [6,7].”
BackgroundRadun, R., & Trauner, M. (2021) · Seminars in Liver Disease · doi:10.1055/s-0041-1731707 · Cited by 83
Kong, B., Zhang, M., Huang, M., Rizzolo, D., Armstrong, L. E., Schumacher, J. D., Chow, M. D., Lee, Y., & Guo, G. L. (2019) · Digestive and Liver Disease · doi:10.1016/j.dld.2018.12.026 · Cited by 78
Nuclear bile acid receptor FXR in the hepatic regeneration
Chen, W., Wang, Y., Meng, Z., Zhang, L., & Huang, W. (2010) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2010.12.006 · Cited by 58
“Recently, several new functions of FXR beyond metabolic regulation have been identified [16–19].”
BackgroundSelf-citationBile acid receptors and signaling crosstalk in the liver, gut and brain
Ferrell, J. M., & Chiang, J. Y. L. (2021) · Liver Research · doi:10.1016/j.livres.2021.07.002 · Cited by 72
Role of farnesoid X receptor in inflammation and resolution
Shaik, F. B., Prasad, D. V. R., & Narala, V. R. (2014) · Inflammation Research · doi:10.1007/s00011-014-0780-y · Cited by 69
“FXR with or without exogenous ligand was able to inhibit NF-jB pathway at the level of gene transcription in HepG2 cells and FXR agonist GW4064 represses the expression of NF-jB regulated genes in both HepG2 and mouse primary hepatocytes by decreasing the binding activity between NF-jB and DNA sequence [74].”
BackgroundPharmacological agents for NASH
Ratziu, V. (2013) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2013.193 · Cited by 59
Targeting Farnesoid X receptor (FXR) for developing novel therapeutics against cancer
Girisa, S., Henamayee, S., Parama, D., Rana, V., Dutta, U., & Kunnumakkara, A. B. (2021) · Molecular Biomedicine · doi:10.1186/s43556-021-00035-2 · Cited by 67
Burrin, D. G., Ng, K., Stoll, B., & de Pipaón, M. S. (2014) · Advances in Nutrition · doi:10.3945/an.113.004796 · Cited by 69
Thomas, C. E., Luu, H. N., Wang, R., Xie, G., Adams‐Haduch, J. M., Jin, A., Koh, W., Jia, W. P., Behari, J., & Yuan, J. (2021) · Cancers · doi:10.3390/cancers13112648 · Cited by 78
Gut Microbiota and Host Reaction in Liver Diseases
Fukui, H. (2015) · Microorganisms · doi:10.3390/microorganisms3040759 · Cited by 64
“In addition to other studies supporting the beneficial effect of FXR ligands on liver inflammation and fibrosis [100–102,104], the fact that FXR-deficient mice fed a methionine/choline-deficient diet”
BackgroundZhan, L., Liu, H.-X., Fang, Y., Kong, B., He, Y.-Q., Zhong, X.-B., Fang, J.-W., Wan, Y., & Guo, G. L. (2014) · PLoS ONE · doi:10.1371/journal.pone.0105930 · Cited by 62
“In addition, it has been shown that FXR is also involved in lipid and glucose homeostasis, inflammation, and tumorigenesis [4–7].”
BackgroundDongiovanni, P., Paolini, E., Corsini, A., Sirtori, C. R., & Ruscica, M. (2021) · European Journal of Clinical Investigation · doi:10.1111/eci.13519 · Cited by 73
Molecular Mechanisms of Drug Transporter Regulation
Tirona, R. G. (2010) · Handbook of experimental pharmacology · doi:10.1007/978-3-642-14541-4_10 · Cited by 64
Structure-guided discovery of bile acid derivatives for treating liver diseases without causing itch
Yang, J. J. J., Zhao, T., Fan, J., Zou, H., Lan, G., Guo, F., Shi, Y., Ke, H., Yu, H., Yue, Z., et al. (2024) · Cell · doi:10.1016/j.cell.2024.10.001 · Cited by 75
He, J.-L., Zhao, K., Zheng, L., Xu, Z., Gong, W., Chen, S., Shen, X.-D., Huang, G., Gao, M., Zeng, Y.-J., et al. (2015) · Molecular Cancer · doi:10.1186/s12943-015-0427-9 · Cited by 60
“Besides its regulation on miR-122, FXR uses other mechanisms to protect against HCC including the repression of NF-κB activation in hepatocytes [20], indicating that its anti-inflammatory properties may contribute to HCC prevention.”
BackgroundOrigins of Portal Hypertension in Nonalcoholic Fatty Liver Disease
Baffy, G. (2018) · Digestive Diseases and Sciences · doi:10.1007/s10620-017-4903-5 · Cited by 64
The farnesoid X receptor (FXR) as a new target in non-alcoholic steatohepatitis
Cariou, B. (2008) · Diabetes & Metabolism · doi:10.1016/s1262-3636(08)74605-6 · Cited by 58
Lim, M. Y. C., & Ho, H. K. (2023) · Biochemical Pharmacology · doi:10.1016/j.bcp.2023.115985 · Cited by 60
Recent advances in understanding and managing cholestasis
Wagner, M., & Trauner, M. (2016) · F1000Research · doi:10.12688/f1000research.8012.1 · Cited by 53
Willart, M. A. M., van Nimwegen, M., Grefhorst, A., Hammad, H., Moons, L. M. G., Hoogsteden, H. C., Lambrecht, B. N., & KleinJan, A. (2012) · Allergy · doi:10.1111/all.12019 · Cited by 60
Chen, W., Fu, X., Dong, B., Wang, Y., Shiah, S., Moore, D. D., & Huang, W. (2012) · Hepatology · doi:10.1002/hep.25766 · Cited by 62
Self-citationDuan, R., Huang, K., Guan, X., Li, S., Xia, J., Shen, M., Sun, Z., & Yu, Z. (2022) · Food and Chemical Toxicology · doi:10.1016/j.fct.2022.112948 · Cited by 62
FXR induces SOCS3 and suppresses hepatocellular carcinoma
Guo, F., Xu, Z., Zhang, Y., Jiang, P., Huang, G., Chen, S., Lyu, X., Zheng, P., Zhao, X., Zeng, Y., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.5314 · Cited by 50
Yi, T., Li, X.-F., Yao, S., Wang, L., Chen, Y.-H., Zhao, D., Johnston, H. F., Young, J. S., Liu, H., Todorov, I., et al. (2011) · Journal of Immunology · doi:10.4049/jimmunol.1002939 · Cited by 57
Ciaula, A. D., Bonfrate, L., Khalil, M., & Portincasa, P. (2023) · Internal and Emergency Medicine · doi:10.1007/s11739-023-03343-3 · Cited by 53
“The use of FXR agonists leads to a reduced hepatic inflammation and fibrosis secondary to a concentration-dependent suppression of NF-κB-mediated inflammation [61].”
BackgroundPang, J., Raka, F., Heirali, A., Shao, W., Liu, D., Gu, J., Feng, J. N., Mineo, C., Shaul, P. W., Qian, X., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-38259-1 · Cited by 58
NOX as a Therapeutic Target in Liver Disease
Matuz‐Mares, D., Vázquez‐Meza, H., & Vilchis‐Landeros, M. M. (2022) · Antioxidants · doi:10.3390/antiox11102038 · Cited by 58
Wang, D. Q. ‐., Portincasa, P., & Neuschwander‐Tetri, B. A. (2013) · Comprehensive physiology · doi:10.1002/cphy.c130001 · Cited by 41
Alcohol, the gut microbiome, and liver disease
Jew, M., & Hsu, C. L. (2023) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.16199 · Cited by 63
Meadows, V., Kennedy, L., Ekser, B., Kyritsi, K., Kundu, D., Zhou, T.-H., Chen, L.-X., Pham, L., Wu, N., Demieville, J., et al. (2021) · Hepatology · doi:10.1002/hep.32028 · Cited by 55
Arrese, M., & Karpen, S. J. (2010) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2010.2 · Cited by 54
Vincenzo, F. D., Puca, P., Lopetuso, L. R., Petito, V., Masi, L., Bartocci, B., Murgiano, M., Felice, M. D., Petronio, L., Gasbarrini, A., et al. (2022) · Nutrients · doi:10.3390/nu14132664 · Cited by 63
“Indeed, FXR activation by FXR agonists determined the inhibition of the NF-kB inflammatory pathway in a TNFadependent way, whereas the hepatic activation of NF-kB suppressed FXR-mediated gene expression [26].”
BackgroundThe FXR agonist obeticholic acid inhibits the cancerogenic potential of human cholangiocarcinoma
Matteo, S. D., Nevi, L., Costantini, D., Overi, D., Carpino, G., Safarikia, S., Giulitti, F., Napoletano, C., Manzi, E., Rose, A. M. D., et al. (2019) · PLoS ONE · doi:10.1371/journal.pone.0210077 · Cited by 63
Activation of FXR protects against renal fibrosis via suppressing Smad3 expression
Zhao, K., He, J.-L., Zhang, Y., Xu, Z., Xiong, H.-J., Gong, R., Li, S., Chen, S., & He, F. (2016) · Scientific Reports · doi:10.1038/srep37234 · Cited by 54
Clinical application of transcriptional activators of bile salt transporters
Baghdasaryan, A., Chiba, P., & Trauner, M. (2013) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2013.12.001 · Cited by 57
Emerging Molecular Targets for the Treatment of Nonalcoholic Fatty Liver Disease
Musso, G., Gambino, R., & Cassader, M. (2010) · Annual Review of Medicine · doi:10.1146/annurev.med.60.101107.134820 · Cited by 87
The gut microbiota-bile acid axis in cholestatic liver disease
Sun, D., Xie, C., Zhao, Y. M., Liao, J., Li, S., Zhang, Y., Wang, D., Hua, K., Gu, Y., Du, J., et al. (2024) · Molecular Medicine · doi:10.1186/s10020-024-00830-x · Cited by 56
Allegra, A., Musolino, C., Tonacci, A., Pioggia, G., & Gangemi, S. (2020) · Cancers · doi:10.3390/cancers12040805 · Cited by 53
“FXR has a main action in liver metabolism, liver regeneration and prevention of hepatocarcinogenesis [40].”
BackgroundShan, H.-M., Zang, M., Zhang, Q., Shi, R.-B., Shi, X.-J., Mamtilahun, M., Liu, C., Luo, L.-L., Tian, X., Zhang, Z., et al. (2020) · Journal of Neuroinflammation · doi:10.1186/s12974-020-01838-w · Cited by 53
“In addition, previous studies showed that FXR could modulate TLR4/MyD88-mediated inflammation and also a modulator of NF-κB-mediated hepatic inflammation [36, 37].”
Self-citationFarnesoid-X receptor as a therapeutic target for inflammatory bowel disease and colorectal cancer
Zhou, M., Wang, D., Li, X., Cao, Y., Yi, C., Ocansey, D. K. W., Zhou, Y., & Mao, F. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1016836 · Cited by 49
Src‐mediated crosstalk between FXR and YAP protects against renal fibrosis
Kim, D., Choi, H., Park, J. S., Kim, C. S., Bae, E. H., Kwon, S., & Kim, S. W. (2019) · The FASEB Journal · doi:10.1096/fj.201900325r · Cited by 58
Thomas, F. C., Mudaliar, M., Tassi, R., McNeilly, T. N., Burchmore, R., Burgess, K. E., Herzyk, P., Zadoks, R. N., & Eckersall, P. D. (2016) · Molecular BioSystems · doi:10.1039/c6mb00289g · Cited by 54
Cystic Fibrosis Related Liver Disease—Another Black Box in Hepatology
Staufer, K., Halilbasic, E., Trauner, M., & Kazemi-Shirazi, L. (2014) · International Journal of Molecular Sciences · doi:10.3390/ijms150813529 · Cited by 58
“FXR exerts its anti-inflammatory effects among others via inhibition of hepatocellular nuclear factor κB (NF-κB) activation and induction of tumor necrosis factor α (TNFα) inducible nitric oxide synthase and cyclooxygenase-2 [66].”
BackgroundFarnesoid X Receptor as Target for Therapies to Treat Cholestasis-Induced Liver Injury
Petrescu, A. D., & DeMorrow, S. (2021) · Cells · doi:10.3390/cells10081846 · Cited by 48
Roth, J. D., Veidal, S. S., Fensholdt, L. K. D., Rigbolt, K. T. G., Papazyan, R., Nielsen, J. C., Feigh, M., Vrang, N., Young, M. A., Jelsing, J., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-45178-z · Cited by 54
Schumacher, J. D., & Guo, G. L. (2019) · Handbook of experimental pharmacology · doi:10.1007/164_2019_228 · Cited by 64
Efficacy and safety of anti-hepatic fibrosis drugs
Damiris, K., Tafesh, Z., & Pyrsopoulos, N. (2020) · World Journal of Gastroenterology · doi:10.3748/wjg.v26.i41.6304 · Cited by 52
Du, J., Chen, Q., Li, Y., Xiang, X., Xu, W., Mai, K., & Ai, Q. (2020) · Journal of Nutrition · doi:10.1093/jn/nxaa185 · Cited by 50
Role of the intestinal microbiome in liver fibrosis development and new treatment strategies
Zhou, R., Fan, X., & Schnabl, B. (2019) · Translational research · doi:10.1016/j.trsl.2019.02.005 · Cited by 53
Fei, J., Fu, L., Hu, B., Chen, Y.-H., Zhao, H., Xu, D.-X., & Li, J.-B. (2019) · International Immunopharmacology · doi:10.1016/j.intimp.2018.11.005 · Cited by 48
Metadata
- Authors
- Wang, Y.-D., Chen, W.-D., Wang, M., Yu, D., Forman, B. M., & Huang, W.
- Affiliations
- City Of Hope National Medical Center (US)
- Corresponding author
- Huang, Wendong
- Venue
- Hepatology
- Published
- 2008-11
- Volume
- 48
- Issue
- 5
- Pages
- 1632-1643
- ISSN
- 0270-9139 (ISSN-L)
- PMC
- PMC3056574
- OpenAlex
- W2021998283
- Cited by
- 639
- References
- 52
- Citations by year
- 2026: 30 · 2025: 46 · 2024: 44 · 2023: 46 · 2022: 51 · 2021: 54 · 2020: 45 · 2019: 42 · 2018: 31 · 2017: 42 · 2016: 38 · 2015: 29 · 2014: 31 · 2013: 27 · 2012: 27
- FWCI
- 9.67
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Hepatology (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Sidney Kimmel Foundation for Cancer Research
- Sidney Kimmel Foundation
- National Cancer Institute (P30CA033572)
- Topics
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Health Sciences › Medicine › Hepatology › Liver physiology and pathology
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › NF-κB Signaling Pathways
- Keywords
- farnesoid X receptor, nuclear factor-kappaB, liver inflammation, hepatoprotection, lipopolysaccharide, inducible nitric oxide synthase, cyclooxygenase-2, CXCL10, interferon-gamma, liver necrosis, hepatocarcinogenesis, anti-apoptotic genes
- MeSH terms
- Receptor, Farnesoid X-Activated, Animals, Cell Line, DNA-Binding Proteins, Homeostasis, Humans, Inflammation, Kidney, Liver, Liver Neoplasms, Necrosis, RNA, Messenger, Transcription Factors, Tumor Necrosis Factor-alpha, NF-kappa B, Receptors, Cytoplasmic and Nuclear, Hepatoblastoma, Mice, Knockout, Cell Line, Tumor, Mice, Cyclooxygenase 2, Nitric Oxide Synthase Type II
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
